| (19) |
 |
|
(11) |
EP 2 371 388 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
28.03.2012 Bulletin 2012/13 |
| (43) |
Date of publication A2: |
|
05.10.2011 Bulletin 2011/40 |
| (22) |
Date of filing: 19.10.2005 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE
SI SK TR |
|
Designated Extension States: |
|
AL BA HR MK YU |
| (30) |
Priority: |
20.10.2004 US 620413 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
05815641.5 / 1802344 |
| (71) |
Applicant: Genentech, Inc. |
|
South San Francisco CA 94080-4990 (US) |
|
| (72) |
Inventors: |
|
- Andya, James, D.
Millbrae, CA 94030 (US)
- GWEE, Shiang, C.
Pacifica, CA 94044 (US)
- Liu, Jun
Pacifica, CA 94044 (US)
- Shen, Ye
San Francisco, CA 94112 (US)
|
| (74) |
Representative: Walton, Seán Malcolm et al |
|
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS
London
EC2V 8AS (GB) |
|
| |
|
| (54) |
Antibody formulations |
(57) The present application describes antibody formulations, including monoclonal antibodies
formulated in histidine-acetate buffer, as well as a formulation comprising an antibody
that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising
an antibody that binds to DR5 (for example, Apomab).